WuXi AppTec | Latest News & Updates - Nov 18, 2024 Release

WuXi AppTec opened its first high potency oral drug product manufacturing facility in 2022, expanding its integrated drug product R&D and manufacturing services...


Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡


WuXi AppTec

🌎 wuxiapptec.com

WuXi AppTec is a global company headquartered in Shanghai, providing a comprehensive range of R&D and manufacturing services to the pharmaceutical and biotech industries. With operations across Asia, Europe, and North America, the company supports over 6,000 customers in advancing healthcare products through integrated services that include drug discovery, clinical research, and advanced therapies. WuXi AppTec aims to enable every drug to be made and every disease to be treated, receiving recognition for its commitment to sustainability and innovation.


WuXi AppTec - Latest News and Updates

  • WuXi AppTec opened its first high potency oral drug product manufacturing facility in 2022, expanding its integrated drug product R&D and manufacturing services.
  • WuXi AppTec has upgraded its OncoWuXi database to version 3.0, enhancing user experience and expanding its functionality and scope.
  • WuXi AppTec opened a new R&D center in Changzhou, China on November 15, 2024.
  • WuXi AppTec has updated its location details and services across various cities in China, including Shanghai, Changzhou, Suzhou, Nanjing, Nantong, Wuxi, and Chengdu, with specific focus on drug discovery, CDMO services, and cell therapy.
  • Emma Quirk has joined WuXi AppTec as Director, CMC, EU in the Greater Liverpool Area, previously serving as Director at Biohaven Pharmaceuticals.
  • Robert Cissell has joined WuXi AppTec as Sr. Director Business Development in the Louisville Metropolitan Area, previously holding a position in a similar role.
  • At SITC 2024, WuXi AppTec presented a poster on using imiquimod to induce psoriasis-like symptoms in NHPs to aid in evaluating psoriasis treatments.
  • WuXi AppTec's Couvet site in Switzerland received a 2024 silver medal from EcoVadis for its sustainability efforts, ranking in the top 9% of all rated companies.
  • WuXi AppTec has been ranked #1 in the global Life Sciences Tools & Services sector in the 2024 S&P Global Corporate Sustainability Assessment as of November 11, 2024.
  • WuXi AppTec will exhibit at the EBF 2024 Open Symposium in Barcelona from November 20-22, showcasing two poster presentations on antibody detection methods.

Sign up to receive regular updates


If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.